Get the Stockscreener App
1.15
6.48%
0.07
After Hours:
1.15
Affimed N V stock is traded at $1.15, with a volume of 347.25K.
It is up +6.48% in the last 24 hours and down -23.84% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$1.08
Open:
$1.1
24h Volume:
347.25K
Relative Volume:
1.15
Market Cap:
$18.85M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-0.1364
EPS:
-8.428
Net Cash Flow:
$-132.44M
1W Performance:
-2.54%
1M Performance:
-23.84%
6M Performance:
-79.24%
1Y Performance:
-80.51%
1-Day Range:
$1.05
$1.16
1-Week Range:
$1.03
$1.16
52-Week Range:
$1.03
$8.95
Affimed N V Stock (AFMD) Company Profile
Compare AFMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
1.15 | 18.85M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance
Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire
Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):